7:06 am Biogen Idec and Sobi announce positive top-line efficacy and safety results from Phase 3 pediatric study of investigational therapy eloctate (rFVIIIFc) for hemophilia A; data showed twice-weekly prophylactic dosing with ELOCTATE mai
View todays social media effects on BIIB
View the latest stocks trending across Twitter. Click to view dashboard